The objective of the present study was to evaluate the potential of solid dispersion adsorbate
(SDA) to improve the solubility and bioavailability of rivaroxaban (RXN). SDA of RXN was …

Rivaroxaban (RXB) is an orally active direct inhibitor of the activated serine protease Factor
Xa, given as monotherapy in the treatment of venous thromboembolism (VTE). It has been …

The purpose of this study was to investigate the efficacy of hydrophilic polymers in a solid
dispersion formulation in improving the solubility and dissolution rate of rivaroxaban (RXB) …

Rivaroxaban (RXN) finds use in the management of pulmonary embolism and deep vein
thrombosis. Its poor solubility (5–7 µg/mL) and P-gp-mediated efflux from intestinal lining …

Recent advancements in the formulation of solid dosage forms involving active ingredient-
cyclodextrin complexes have garnered considerable attention in pharmaceutical research …

This study aims to improve the RXB bioavailability using hybrid nanoparticles. A modified
melt dispersion technique created different formulas with varying GMO-SAIB: RXB and GMO …

Rivaroxaban (RXB), a novel oral anticoagulant that directly inhibits factor Xa, is a poorly
soluble drug belonging to Biopharmaceutics Classification System (BCS) class II. In this …

Rivaroxaban (RXB) is a class II drug, according to the Biopharmaceutics Classification
System. Since its bioavailability is low at high doses, dose proportionality is not achieved for …

This study aimed to investigate the use of Sucrose acetate isobutyrate (SAIB) and Glyceryl
monooleate (GMO) as co-formers for creating Cubosomes and SAIB-based nanodispersions …

In this paper, a novel self-nanoemulsifying drug delivery system (SNEDDS) was used to
improve the oral bioavailability in fasted state and diminish the food effect for rivaroxaban …